Life sciences news
-
Oxurion reaches enrollment target in KALAHARI Phase 2, Part B trial of novel PKal inhibitor THR-149 in diabetic macular edema
Friday May 26th 2023
Read more
-
Galapagos announces start of Phase 2 study with selective TYK2 inhibitor, GLPG3667, in patients with dermatomyositis
Wednesday May 24th 2023
Read more
-
Sequana Medical announces FDA clearance of IND application for DSR® 2.0 for treatment of congestive heart failure
Tuesday May 2nd 2023
Read more
-
Galapagos initiates Phase 3 program with filgotinib in patients with active axial spondyloarthritis
Thursday April 27th 2023
Read more
-
VIB and Ghent University develop new mRNA vaccines against bacterial infections
Wednesday April 26th 2023
Read more
-
Bimekizumab Phase 3 data in hidradenitis suppurativa show clinically meaningful, deep and maintained response over 48 weeks
Monday March 20th 2023
Read more
-
Oxurion provides update on recruitment for KALAHARI Phase 2, Part B trial of novel PKal inhibitor THR-149 in diabetic macular edema and announces Board changes
Tuesday March 14th 2023
Read more
-
Mithra announces promising topline safety results from Donesta® Phase 3 Study in North America
Monday March 6th 2023
Read more
-
Become a flanders.bio member
Your news here?
-
Mithra announces compelling initial preclinical data in its research collaboration on novel tyrosine kinase inhibitors with BCI Pharma
Thursday March 2nd 2023
Read more
-
Sequana Medical announces positive results from CHIHUAHUA, Phase 1 clinical trial of second-generation DSR product for congestive heart failure
Wednesday March 1st 2023
Read more
-
Galapagos announces topline results from Phase 3 DIVERSITY trial of filgotinib in Crohn’s disease
Thursday February 9th 2023
Read more
More info?
Contact us
Ellen Telleir
Communication Coordinator
